WO2017037645A1 - Formulations pharmaceutiques stables de tériflunomide - Google Patents

Formulations pharmaceutiques stables de tériflunomide Download PDF

Info

Publication number
WO2017037645A1
WO2017037645A1 PCT/IB2016/055231 IB2016055231W WO2017037645A1 WO 2017037645 A1 WO2017037645 A1 WO 2017037645A1 IB 2016055231 W IB2016055231 W IB 2016055231W WO 2017037645 A1 WO2017037645 A1 WO 2017037645A1
Authority
WO
WIPO (PCT)
Prior art keywords
teriflunomide
dosage form
silicon dioxide
tablet dosage
pharmaceutical tablet
Prior art date
Application number
PCT/IB2016/055231
Other languages
English (en)
Inventor
Chandrashekhar Kocherlakota
Nagaraju Banda
Original Assignee
Leiutis Pharmaceuticals Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiutis Pharmaceuticals Pvt Ltd filed Critical Leiutis Pharmaceuticals Pvt Ltd
Publication of WO2017037645A1 publication Critical patent/WO2017037645A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds

Definitions

  • Teriflunomide is the predominant active metabolite of Leflunomide, which has been marketed as a disease-modifying therapy for rheumatoid arthritis in the United States since September 1998. It is an immunomodulatory agent with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHO-DH), required for the de novo pyrimidine synthesis. As a consequence, Teriflunomide reduces the proliferation of dividing cells that need de novo synthesis of pyrimidine to expand.
  • DHO-DH dihydroorotate dehydrogenase
  • Teriflunomide (Z)-2-cyano-3-hydroxy-but-2-enoicacid- (4-trifluoromethylphenyl)-ami mical structure:
  • Teriflunomide is formulated as film-coated tablets for oral administration and is available as Aubagio ® in the US. It is used for the treatment of patients with relapsing forms of multiple sclerosis.
  • Aubagio tablets contain 7 mg or 14 mg of Teriflunomide, lactose monohydrate, corn starch, hydroxypropylcellulose, microcrystalline cellulose, sodium starch glycolate and magnesium stearate.
  • the film coating for the 14 mg tablet is made of hypromellose, titanium dioxide, talc, polyethylene glycol and indigo carmine aluminum lake. In addition to these, the 7 mg tablet film coating includes iron oxide yellow.
  • U.S. patent 5,679,709 to Bartlett et al. discloses Teriflunomide compound and Teriflunomide composition useful for treating autoimmune diseases.
  • U.S. patent 6,794,410 to Wettstein et al. discloses a method of treatment of multiple sclerosis with Teriflunomide or its stereoisomer, or a pharmaceutically acceptable salt thereof.
  • U.S. patent 8,802,735 to Hauck et al. discloses a solid pharmaceutical composition of Teriflunomide.
  • the patent teaches that Teriflunomide tablets cannot be made with colloidal silicon dioxide as it leads to an unstable product.
  • the patent teaches that Teriflunomide tablets without colloidal silicon dioxide display significantly reduced formation of degradants, compared to Teriflunomide tablets containing colloidal silicon dioxide.
  • the present invention is directed to stable formulations of Teriflunomide containing silicon dioxide.
  • One aspect of the present invention is to provide stable pharmaceutical formulations of Teriflunomide, wherein the composition comprises colloidal silicon dioxide.
  • Another aspect of the present invention is directed to the preparation of stable pharmaceutical formulations of Teriflunomide in the form of tablets comprising colloidal silicon dioxide with other pharmaceutically acceptable excipients.
  • the present invention is directed to the preparation of stable pharmaceutical formulations of Teriflunomide comprising of colloidal silicon dioxide and other pharmaceutically acceptable excipients.
  • Teriflunomide refers to the pharmaceutically acceptable derivatives, such as salts, solvates, hydrates and polymorphs thereof.
  • the prior art references disclose that Teriflunomide tablets without colloidal silicon dioxide result in a product with lesser degradants compared to Teriflunomide tablets containing colloidal silicon dioxide.
  • the presence of colloidal silicon dioxide in the formulation is preferred, as it is used to improve flowability.
  • the present invention is directed to formulations of Teriflunomide tablets comprising colloidal silicon dioxide without adversely affecting the stability.
  • colloidal silicon dioxide is submicroscopic fumed silica, also known as pyrogenic silica or silicon dioxide. Silicon dioxide is generally recognized as safe by the FDA.
  • the present invention provides tablet dosage formulations of Teriflunomide comprising of colloidal silicon dioxide, diluent, disintegrant, binder, lubricant and optionally other pharmaceutically acceptable excipients.
  • the percentage of silicon dioxide in the formulation ranges from about 0.01% to 3%, based on total weight of the formulation.
  • the invention comprises one or more pharmaceutically acceptable excipients selected from the group consisting of granulating agents, solvents, glidants, surfactants, preservatives, pH adjusting agents, solubilizers, emulsifiers, plasticizers and the like.
  • the number of excipients that can be included in a formulation is not limited.
  • diluents/fillers include, but not limited to, celluloses, cellulose acetate, microcrystalline cellulose, co-processed microcrystalline celluloses (such as various grades of Avicel), silicified microcrystalline cellulose, dextrates, dextrin, dextrose, fructose, glyceryl palmitostearate, hydrogenated vegetable oil, kaolin, lactitol, lactose, maltitol, mannitol, maltodextrin, maltose, pregelatinized starch, sodium chloride, sorbitol, starches, sucrose, glucose, trehalose, erythritol, fructose, calcium sulphate, dibasic calcium phosphate, talc and xylitol or a mixture of one or more of said diluents.
  • celluloses cellulose acetate, microcrystalline cellulose, co-processed microcrystalline celluloses (such as various grades of Avicel), silic
  • Suitable binders include, but not limited to, celluloses such as microcrystalline cellulose, modified celluloses such as low substituted hydroxypropyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, hydroxyethyl methylcellulose, cellulose gum, xanthan gum, sugars (such as sucrose, glucose, amylose, maltodextrin, dextrose and the like), starches such as corn or potato starch, pregelatinized starches, polyvinyl alcohol- polyethylene glycol graft copolymer, copovidone, povidone, carbomers, polycarbophil, polyethylene oxide, polyethylene glycol or a combination of suitable binders.
  • celluloses such as microcrystalline cellulose
  • modified celluloses such as low substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, hydroxyethyl methylcellulose, cellulose gum, xanthan gum
  • sugars
  • disintegrants include, but not limited to starches, partially pregelatinized starches, sodium starch glycolate, pregelatinized starch, alginic acid, powdered cellulose, croscarmellose sodium, crospovidone, docusate sodium, guar gum, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, magnesium aluminum silicate, methylcellulose, sodium alginate or a combination of one or more disintegrants.
  • glidants include, but not limited to calcium phosphate, calcium silicate, powdered cellulose, magnesium trisilicate, silicon dioxide, talc, colloidal silica, colloidal silica anhydrous, maize starch and the like.
  • lubricants include, but not limited to, calcium stearate, zinc stearate, magnesium stearate, aluminium stearate, stearic acids, sodium stearyl fumarate, hydrogenated castor oil, light mineral oil, polyethylene glycol, magnesium lauryl sulfate and the like.
  • the present invention also provides a method for preparing stable Teriflunomide tablets.
  • Conventional processes such as direct compression, wet granulation (fluid bed granulation) and dry granulation (slugging and roll compaction) may be used.
  • the compressed tablets are further film coated by non-aqueous coating or aqueous coating or by hydroalcoholic coating.
  • This coating composition contains film-forming substances such as hydroxypropyl methyl cellulose (hypromellose), hydroxyl propyl cellulose, methyl cellulose, polyvinyl alcohol; solvents, colloidal silicon dioxide, optionally other excipients such as plasticizers, lubricants and colourants.
  • film-forming substances such as hydroxypropyl methyl cellulose (hypromellose), hydroxyl propyl cellulose, methyl cellulose, polyvinyl alcohol; solvents, colloidal silicon dioxide, optionally other excipients such as plasticizers, lubricants and colourants.
  • a preferred blend of hydroxypropyl methylcellulose, a plasticizer and a colorant is commercially available under the trade name Opadry ® .
  • Colloidal silicon dioxide is added in the coating composition, to enhance disintegration and dissolution rate.
  • Solvents used for granulation and coating can be either aqueous or non-aqueous solvents. Suitable non-aqueous solvents include, but are not limited to isopropyl alcohol, ethanol, dichloromethane, acetone and the like. Aqueous solvent include water.
  • Teriflunomide tablet formulations prepared according to the invention were tested for dissolution using USP type II (Paddle) apparatus at 50 RPM at 37°C. Teriflunomide tablet formulation prepared without silicon dioxide was taken as a reference product. Comparative dissolution profiles of Teriflunomide tablet formulations prepared without silicon dioxide and Teriflunomide tablet formulations prepared with silicon dioxide were recorded and tabulated in table 1.
  • Table 1 Comparative dissolution profile of Teriflunomide formulations.
  • Teriflunomide, lactose monohydrate, corn starch, hydroxy propyl cellulose, micro crystalline cellulose, sodium starch glycolate and magnesium stearate were blended and co-sifted twice from sieve #40.
  • the co-sifted material was compressed into pentagonal 8mm tablets.
  • Finally the compressed tablets were coated with a coating composition comprising opadry blue and IPA: DCM (50:50).
  • Teriflunomide, lactose monohydrate, corn starch, hydroxy propyl cellulose, micro crystalline cellulose, sodium starch glycolate and magnesium stearate were blended and co-sifted twice from sieve #40.
  • the co-sifted material was compressed into pentagonal 8mm tablets.
  • Finally the compressed tablets were coated with a coating composition comprising of colloidal silicon dioxide, opadry blue and IPA: DCM (50:50).
  • Teriflunomide, lactose monohydrate, corn starch, hydroxy propyl cellulose, micro crystalline cellulose, sodium starch glycolate, colloidal silicon dioxide and magnesium stearate were blended and co-sifted twice from sieve #40.
  • the co-sifted material was compressed into pentagonal 8mm tablets.
  • Finally the compressed tablets were coated with a coating composition comprising of colloidal silicon dioxide, opadry blue and IPA: DCM (50:50).
  • Binder solution paste was prepared mixing water and polyvinylpyrrolidone. Binder was added to preblend and granulated in rapid mixer granulator. The obtained granules were milled and dried in a fluid bed drier. The dried granules were further milled and lubricated with polyethylene glycol followed by compression. The compressed tablets were coated with a coating composition comprising of colloidal silicon dioxide and opadry blue in aqueous/non-aqueous solvents. For aqueous coating 15% w/w suspension was prepared with water. For nonaqueous coating 5% w/w suspension was prepared with dichloromethane: isopropanol (1:1).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques stables de comprimés de tériflunomide comprenant du tériflunomide, du dioxyde de silicium colloïdal et d'autres excipients pharmaceutiquement acceptables. En outre, l'invention concerne un procédé de préparation de comprimés de tériflunomide.
PCT/IB2016/055231 2015-09-02 2016-09-01 Formulations pharmaceutiques stables de tériflunomide WO2017037645A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4638CH2015 2015-09-02
IN4638/CHE/2015 2015-09-02

Publications (1)

Publication Number Publication Date
WO2017037645A1 true WO2017037645A1 (fr) 2017-03-09

Family

ID=58186997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/055231 WO2017037645A1 (fr) 2015-09-02 2016-09-01 Formulations pharmaceutiques stables de tériflunomide

Country Status (1)

Country Link
WO (1) WO2017037645A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020005189A3 (fr) * 2018-06-27 2020-03-12 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques solides d'administration par voie orale comprenant du tériflunomide
WO2020095319A1 (fr) * 2018-11-05 2020-05-14 Sarudbhava Formulations Private Limited Compositions pharmaceutiques topiques de tériflunomide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011032929A1 (fr) * 2009-09-18 2011-03-24 Sanofi-Aventis Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée
WO2013062442A2 (fr) * 2011-10-27 2013-05-02 Общество С Ограниченной Ответственностью "Валента-Интеллект" Composition pour traiter la sclérose en plaques (et variantes)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011032929A1 (fr) * 2009-09-18 2011-03-24 Sanofi-Aventis Formulations de comprimés de (4'-trifluorométhylphényl)-amide de l'acide (z)-2-cyano-3-hydroxy-but-2-énoïque de stabilité améliorée
WO2013062442A2 (fr) * 2011-10-27 2013-05-02 Общество С Ограниченной Ответственностью "Валента-Интеллект" Composition pour traiter la sclérose en plaques (et variantes)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020005189A3 (fr) * 2018-06-27 2020-03-12 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques solides d'administration par voie orale comprenant du tériflunomide
WO2020095319A1 (fr) * 2018-11-05 2020-05-14 Sarudbhava Formulations Private Limited Compositions pharmaceutiques topiques de tériflunomide

Similar Documents

Publication Publication Date Title
CN107530348B (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物
KR101840182B1 (ko) 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일]-1ｈ-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물
NZ555901A (en) Matrix type sustained-release preparation containing donepezil hydrochloride and / or memantine hydrochloride
WO2015128853A1 (fr) Compositions de dapagliflozin
WO2017208136A1 (fr) Composition pharmaceutique de co-cristal de dapagliflozine
WO2012172461A1 (fr) Compositions pharmaceutiques de febuxostat
US20130344150A1 (en) Direct compression tablets of otilonium
US11576917B2 (en) Pharmaceutical compositions comprising Ibrutinib
KR101331723B1 (ko) Ｈｃｖ 중합효소 억제제 전구약물을 포함하는 약학 조성물
EP3435987A1 (fr) Composition pharmaceutique de dapagliflozine
WO2016079687A1 (fr) Composition pharmaceutique orale de tériflunomide
WO2017037645A1 (fr) Formulations pharmaceutiques stables de tériflunomide
US8772346B2 (en) Pharmaceutical composition
WO2007049291A1 (fr) Nouvelles formes solides de dosage de valsartan et d'hydrochlorothiazide
WO2013001441A1 (fr) Formulations sèches de febuxostat
EP3829547A1 (fr) Composition pharmaceutique de ticagrélor
WO2016113754A2 (fr) Nouvelles formes posologiques orales de fumarate de diméthyle
WO2019116386A1 (fr) Compositions pharmaceutiques orales d'aprémilast amorphe et ses procédés de préparation
WO2022153330A1 (fr) Compositions pharmaceutiques comprenant de l'acalabrutinib
WO2021106004A1 (fr) Composition pharmaceutique de s-adénosylméthionine
JP2021518422A (ja) レナリドミドを含む医薬組成物
EP1776102A1 (fr) Preparations de compositions pharmaceutiques stables de nateglinide et procedes de preparation de celles-ci
WO2023195954A1 (fr) Comprimé pelliculé comprenant une dispersion solide de sélexi̇pag
WO2023195953A1 (fr) Comprimé pelliculé comprenant du selexi̇pag
WO2024084496A1 (fr) Compositions pharmaceutiques comprenant du maléate d'acalabrutinib

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16840945

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16840945

Country of ref document: EP

Kind code of ref document: A1